Report Sections

See All Reports

  • HP:0001695: Cardiac arrest
  • Pneumonia (361) Abnormality of the cardiovascular system (36) Respiratory tract infection (36) Neoplasm (29) Hypoxemia (28) Diabetes mellitus (25) Depressivity (24) Thromboembolism (23) Acute kidney injury (22) Abnormal lung morphology (21) Anosmia (19) Hypertension (18) Abnormality of coagulation (15) Pulmonary embolism (15) Pulmonary fibrosis (15) Stroke (14) Arthritis (14) Interstitial pneumonitis (14) Myocardial infarction (12) Type II diabetes mellitus (12) Deep venous thrombosis (11) Rheumatoid arthritis (10) Leukemia (10) Respiratory distress (10) Low levels of vitamin D (10) Behavioral abnormality (9) Mental deterioration (9) Chronic pain (9) Congestive heart failure (8) Myocarditis (8) Type I diabetes mellitus (8) Sepsis (8) Infertility (7) Abnormality of the liver (7) Lymphopenia (7) Inflammation of the large intestine (7) Pulmonary obstruction (7) Pulmonary insufficiency (7) Immunodeficiency (6) Systemic lupus erythematosus (6) Chronic pulmonary obstruction (6) Abnormality of the gastrointestinal tract (6) Neoplasm of the lung (6) Encephalopathy (5) Obesity (5) Lymphoma (5) Autoimmunity (5) Breast carcinoma (5) Disseminated intravascular coagulation (5) Fatigue (5) Abnormality of the kidney (4) Coronary artery atherosclerosis (4) Cardiac arrest (4) Headache (4) Colon cancer (4) Arrhythmia (4) Carcinoma (4) Hypercoagulability (4) Autistic behavior (3) Seizure (3) Cardiomyopathy (3) Dysphagia (3) Migraine (3) Pulmonary arterial hypertension (3) Asthma (3) Bronchiectasis (3) Neoplasm of the pancreas (3) Psoriasiform dermatitis (3) Attention deficit hyperactivity disorder (3) Cutaneous melanoma (3) Neoplasm of head and neck (3) Pulmonary edema (3) Insomnia (3) Neoplasm of the large intestine (3) Renal insufficiency (2) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Psychosis (2) Autism (2) Dementia (2) Abnormality of the endocrine system (2) Abnormality of the thyroid gland (2) Jaundice (2) Hepatic fibrosis (2) Premature birth (2) Abnormal heart morphology (2) Abnormality of blood and blood-forming tissues (2) Fever (2) Diarrhea (2) Hypothermia (2) Neurodegeneration (2) Abnormal intestine morphology (2) Alopecia of scalp (2) Encephalitis (2) Obstructive sleep apnea (2) Male infertility (2) Stillbirth (2) Paroxysmal atrial fibrillation (2) Lymphoid leukemia (2) Myeloproliferative disorder (2) Chronic lymphatic leukemia (2) Renal cell carcinoma (2) Multiple myeloma (2) Abnormal anterior horn cell morphology (2) Amyotrophic lateral sclerosis (2) Sleep apnea (2) Cystoid macular edema (2) Hemeralopia (2) Arteritis (2) Chronic kidney disease (2) Cervix cancer (2) Cholangitis (2) Cholangiocarcinoma (2) Myositis (2) Neuroendocrine neoplasm (2) Neoplasm of the rectum (2) Mania (2) Nephritis (1) Menorrhagia (1) Conductive hearing impairment (1) Cataract (1) Amblyopia (1) Periodontitis (1) Abnormality of the nervous system (1) Oligospermia (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Abnormality of the skin (1) Lymphedema (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Spastic diplegia (1) Hemiparesis (1) Meningitis (1) Cerebral hemorrhage (1) Abnormal joint morphology (1) Hepatic failure (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Cor pulmonale (1) Tachycardia (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Angina pectoris (1) Pancreatitis (1) Premature rupture of membranes (1) Weight loss (1) Thrombocytopenia (1) Autoimmune thrombocytopenia (1) Gastroesophageal reflux (1) Anorexia (1) Esophageal varix (1) Apnea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Memory impairment (1) Difficulty walking (1) Hyperkinetic movements (1) Alzheimer disease (1) Increased intracranial pressure (1) Colitis (1) Biliary cirrhosis (1) Hypotension (1) Vascular dilatation (1) Atherosclerosis (1) Osteoarthritis (1) Tachypnea (1) Hypoventilation (1) Myelodysplasia (1) Neoplasm of the liver (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Reduced factor VIII activity (1) Skeletal muscle atrophy (1) Myalgia (1) Muscular dystrophy (1) Neonatal death (1) Increased body weight (1) Neoplasm of the nervous system (1) Malnutrition (1) Thrombophlebitis (1) Ventricular tachycardia (1) Acute myeloid leukemia (1) Dilatation of the cerebral artery (1) Knee osteoarthritis (1) Monoclonal immunoglobulin M proteinemia (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the stomach (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Renal neoplasm (1) Uterine neoplasm (1) Testicular neoplasm (1) Intestinal atresia (1) Tonsillitis (1) Inflammatory abnormality of the skin (1) Placental abruption (1) Postprandial hyperglycemia (1) Endometrial carcinoma (1) Erythroid hypoplasia (1) Asterixis (1) Glioblastoma multiforme (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Morphea (1) Allergy (1) Non-Hodgkin lymphoma (1) Retinal vein occlusion (1) Heart block (1) Dyspareunia (1) Ductal carcinoma in situ (1) Endometriosis (1) Cardiogenic shock (1) Vulvar neoplasm (1) Addictive behavior (1) Femur fracture (1) Neonatal sepsis (1) Glue ear (1) Neoplasm of the central nervous system (1) Abnormality of movement (1) Ulcerative colitis (1) Crohn's disease (1) Endocarditis (1) Toxemia of pregnancy (1) Neoplasm of the larynx (1) Ovarian neoplasm (1) Vaginal neoplasm (1) Cellulitis (1) Bulimia (1) Atelectasis (1) Esophageal neoplasm (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0001695: Cardiac arrest

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO

    Correlated Drug Terms (8)

    Name (Synonyms) Correlation
    drug693 Cardiopulmonary resuscitation Wiki 0.50
    drug1038 Direct laryngoscopy Wiki 0.50
    drug3139 Standard of Care (Intravenous access) Wiki 0.50
    Name (Synonyms) Correlation
    drug2037 Modified Rankin score Wiki 0.50
    drug2081 NIO® (Intraosseous access) Wiki 0.50
    drug3553 Vie Scope laryngoscopy Wiki 0.50
    drug3842 iv Tocillizumab (TCZ) Wiki 0.50
    drug3827 in-hospital mortality rate Wiki 0.50

    Correlated MeSH Terms (2)

    Name (Synonyms) Correlation
    D006323 Heart Arrest NIH 1.00
    D004630 Emergencies NIH 0.08

    Correlated HPO Terms (0)

    Name (Synonyms) Correlation

    Clinical Trials

    Navigate: Correlations   HPO

    There are 4 clinical trials

    1 Safety and Efficacy of Endotracheal Intubation by Paramedics in Suspected/Confirmed COVID-19 Patients Under Cardiac Arrest Using Vie Scope Laryngoscope

    The safety and efficacy of a laryngoscopy as a primary intubation tool in urgent endotracheal intubation of cardiac arrest patients with suspected/confirmed COVID-19 has not been well-described in the literature. This study will answer whether using a Vie Scope laryngoscope will impact on the efficacy and safety of intubation compared with a traditional direct laryngoscopy.

    1. Intubation Complication
    2. Intubation; Difficult or Failed
    3. Cardiac Arrest
    4. Influenza
    5. Safety Issues
    1. Procedure: Direct laryngoscopy
    2. Procedure: Vie Scope laryngoscopy
    MeSH:Heart Arrest
    HPO:Cardiac arrest Cardiorespiratory arrest

    Primary Outcomes

    Description: Definition of failed intubation: Time to intubation is longer than 120 seconds or wrong placement of endotracheal tube (For example : Esophageal intubation etc.)

    Measure: Intubation success rate during at the first laryngoscopy

    Time: 10 min

    Secondary Outcomes

    Description: Intubation difficulty assessed by Intubation difficulty Scale score

    Measure: Intubation difficulty Scale score

    Time: 10 min

    Description: Complications related to tracheal intubation during advanced Cardiopulmonary Resuscitation (CPR): failure, esophageal intubation, mainstem intubation, vomiting, pulmonary aspiration, dental trauma, extubation

    Measure: Complications related to tracheal intubation

    Time: 10 min

    Description: Time to completion of tracheal intubation (TI) procedure measured from the instant that the laryngoscope blade touches the patient to the moment that the tracheal tube cuff is inflated

    Measure: Time to completion of tracheal intubation (TI) procedure

    Time: 10 min

    Description: Duration of the interruption of chest compression during ETI procedure

    Measure: Duration of the interruption of chest compression during ETI procedure

    Time: 10 min

    Description: We will record the best laryngeal View during intubation. We will record according to the Cormack-Lehane Grade system.

    Measure: Laryngeal View during intubation

    Time: 10 min

    Description: self-reported percentage of glottis opening (POGO) score

    Measure: POGO score

    Time: 10 min
    2 Comparison of Intraosseous Versus Intravenous Access in Suspected/Confirmed COVID-19 Patient in Prehospital Setting

    The current COVID-19 pandemic, this is especially since the transmission of SARS-CoV-2 is thought to occur mainly through respiratory droplets generated by coughing and sneezing, by direct contact with contaminated surfaces and because in a large number of patients COVID-19 disease may be asymptomatic. As recommended by the CDC medical personnel should be equipped with full personal protective equipment (PPE) for AGP in contact with suspected/confirmed COVID-19 patient. Therefore, it is reasonable to search for the most effective methods of intravascular access in those conditions.

    1. Emergency Medicine
    2. Cardiopulmonary Arrest
    3. Shock
    1. Device: NIO® (Intraosseous access)
    2. Device: Standard of Care (Intravenous access)
    MeSH:Heart Arrest Emergen Emergencies
    HPO:Cardiac arrest Cardiorespiratory arrest

    Primary Outcomes

    Description: successful placement of intravascular device

    Measure: Success rate of first intravascular access attempt

    Time: 1 day

    Secondary Outcomes

    Description: time to successful access

    Measure: time to successful access

    Time: 1 day

    Description: number of attempts to successful access

    Measure: number of attempts to successful access

    Time: 1 day

    Description: time to therapy including but not limited to time to fluids, antibiotics, and antiarrythmics

    Measure: time to infusion

    Time: 1 day

    Description: complication rates

    Measure: complication rates

    Time: 1 day

    Description: the rate of survival to hospital admission

    Measure: ROSC

    Time: 1 day
    3 Cardiac Arrest Incidence and Outcome Among Patient With COVID-19 Pneumonia in French ICUs

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the novel coronavirus disease 2019 (COVID-19) pandemic. Among COVID-19 complications, in-hospital cardiac arrest (IHCA) was reported with a very poor outcome in a retrospective single-center study (0,7% of 30 days survival with good neurological outcome among IHCA patients with a resuscitation attempt), related to its natural course and management. The incidence of unexpected in-ICU cardiac arrest (ICUCA) due to COVID-19 is still unknown. Additionally, outcome of COVID-19 patients admitted in ICU for an out-of-hospital cardiac arrest (OHCA) is also undescribed. The objective this study is : - to report the incidence of ICUCA among patients hospitalized in French ICU for COVID-19. - to report morbidity and mortality among COVID-19 patients admitted alive in ICU for an OHCA or an IHCA. The secondary objective is to assess outcome and identify risk factors of ICUCA occurrence among patients admitted for COVID-19.

    1. Sars-CoV2
    2. Covid-19
    1. Other: Cardiopulmonary resuscitation
    2. Other: Modified Rankin score
    MeSH:Heart Arrest
    HPO:Cardiac arrest Cardiorespiratory arrest

    Primary Outcomes

    Description: Percentage of unexpected in-intensive care unit cardiac arrest among COVID-19 patients admitted to intensive care unit

    Measure: Incidence of unexpected cardiac arrest

    Time: 7 months

    Secondary Outcomes

    Description: Diabetes, hypertension, smoking, dyslipidemia, coronary artery disease, chronic respiratory insufficiency, chronic heart failure, chronic renal insufficiency, chronic hepatic insufficiency, chronic neurological disease, cancer, malignant hemopathy. Charlson score's minimum and maximum values are 0 and 40 respectively, the lowest score corresponds to a better outcome.

    Measure: Charlson score

    Time: 7 months

    Description: Respiratory failure, neurological impairment, circulatory failure, hepatic failure, haematological failure, renal failure. Sofa score's minimum and maximum values are 0 and 24, the lowest score corresponds to a better outcome

    Measure: Organ failure score at ICU admission and/or before unexpected in-ICU cardiac arrest

    Time: 7 months

    Description: Cardiac origin; Respiratory origin; Metabolic origin; unknown origin

    Measure: Etiology retained to explain cardiac arrest occurrence

    Time: 7 months

    Description: 0 - no symptoms at all - no significant disability despite symptoms; able to carry out all usual duties and activities - Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance - Moderate disability; requiring some help, but able to walk without assistance - Moderately severe disability; unable to walk and attend to bodily needs without assistance - Severe disability; bedridden, incontinent and requiring constant nursing care and attention - Dead

    Measure: Modified Rankin score (mRS) at ICU discharge, at hospital discharge and at 3 months

    Time: 3 months
    4 Does COVID-19 Pandemic Reduce In-hospital Mortality?

    COVID-19, which emerged in China in December 2019, has become a pandemic with its spread to many countries of the world. Although it is suggested that hospital admissions are reduced due to some reasons such as trauma, during COVID-19 pandemic, it is controversial whether in-hospital mortality rates changed. Therefore this multi-centered study aimed to determine how in-hospital mortality effected during the pandemic period according to the specific patient groups.

    1. Covid19
    2. In-hospital Cardiac Arrest
    1. Other: in-hospital mortality rate
    MeSH:Heart Arrest
    HPO:Cardiac arrest Cardiorespiratory arrest

    Primary Outcomes

    Description: During the pandemic (March-July), deaths occurred in hospital will be evaluated.

    Measure: In-hospital mortality

    Time: 4 months

    HPO Nodes


    Data processed on December 13, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  


    4,818 reports on interventions/drugs


    706 reports on MeSH terms


    306 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook